Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Willow Lane Acquisition Corp.WLAC · Entity 48053 | Chief Financial Officer | November 07, 2024 | November 07, 2024 |
| Willow Lane Acquisition Corp. IIWLIIU · Entity 6090 | Chief Financial Officer | January 30, 2026 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Willow Lane Acquisition Corp.
Report date November 07, 2024 · Filed November 07, 2024
This filing explicitly reported no securities owned.
Willow Lane Acquisition Corp. II
Report date January 30, 2026 · Filed January 30, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ensysce Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
Section 16 reporting ended · disclosed 2021-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-06-30 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 F1: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 1, 2021 19:54 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | GrantWarrants · Derivative | 15,000 | $1.00 Strike: $11.50 | $15,000.00 |
DisclosureSEC source: 0001493152-21-015903 · ownership.xml · derivative · entry 1 Peng George · CIK 0001651293 · Former officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-06-30 F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination. F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 17:26 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 13,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-000386 · s108740_form4.xml · nonDerivative · entry 1 Peng George · CIK 0001651293 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,014 F1 · shares: As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F1 · price: As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 18:55 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 733 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-062468 · tv480818_4.xml · nonDerivative · entry 1 Peng George · CIK 0001651293 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,265 F1 · shares: As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration. F1 · price: As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration. F2 · balance_after: Includes an aggregate of 13,251 shares held by Mr. Peng that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not fully exercised. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.